Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Minireviews
    • JVI Classic Spotlights
    • Archive
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JVI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Journal of Virology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Minireviews
    • JVI Classic Spotlights
    • Archive
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JVI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
VIRAL PATHOGENESIS AND IMMUNITY

Characterization of Simian-Human Immunodeficiency Virus Envelope Glycoprotein Epitopes Recognized by Neutralizing Antibodies from Infected Monkeys

Bijan Etemad-Moghadam, Gunilla B. Karlsson, Matilda Halloran, Ying Sun, Dominik Schenten, Mark Fernandes, Norman L. Letvin, Joseph Sodroski
Bijan Etemad-Moghadam
Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gunilla B. Karlsson
Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matilda Halloran
Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ying Sun
Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dominik Schenten
Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Fernandes
Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Norman L. Letvin
Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph Sodroski
Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, and
Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/JVI.72.10.8437-8445.1998
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Fig. 1.
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    Structure of the SHIV-KB9 and -KB9ct chimeras. The top part of the figure shows the genetic composition of the chimeric SHIV used in this study. The SIVmac239-derived elements of the genome are represented by the shaded rectangles, and the HIV-1-specific components are represented by white rectangles. The circles and triangle mark the coding changes that occurred during animal passage. The white circles represent the nucleotide changes in the LTR; the change in the R region is present in both the 3′ and 5′ LTR, and the substitution in U3 is present only in the 3′ LTR. The triangle marks the 140-bp deletion affecting the HIV-1 gp41 tail. The encoded amino acid substitutions in Tat and the gp41 cytoplasmic tail are present in both KB9 and KB9ct, whereas the env ectodomain changes are present only in KB9. The lower portion of the figure indicates the differences in amino acid composition between KB9 and KB9ct. The sequence of KB9ct in this portion of the envelope glycoproteins is identical to that of 89.6.

  • Fig. 2.
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    Temporal emergence of neutralizing antibodies against viruses with homologous envelope glycoproteins. The presence of antibodies able to neutralize recombinant CAT viruses with homologous envelope glycoproteins was assessed by using plasma from infected monkeys at various time points after infection. The horizontal axes designate days postinfection, and the vertical axes show the level of neutralization normalized to the value observed in the presence of preimmune plasma. CEMx174 cells were infected with the respective homologous recombinant viruses in the presence of a 1:50 dilution of plasma from SHIV-KB9ct-infected monkeys (A) or SHIV-KB9-infected monkeys (B). Symbols represent the monkeys designated as shown.

  • Fig. 3.
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    Cross-neutralizing activity in plasma from day 71 postinfection. Preimmune plasma and plasma from day 71 postinfection were used in a 1:50 dilution to assess neutralization of viruses with KB9 and KB9ct envelope glycoproteins. Entry of the recombinant CAT viruses with KB9 envelope glycoproteins (top panel) and with KB9ct envelope glycoproteins (bottom panel) is shown. The animal number and the specific SHIV with which it was infected are indicated at the bottom of the figure. P, samples incubated with preimmune plasma; 71, samples incubated with plasma from day 71.

  • Fig. 4.
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    Comparative neutralization of recombinant envelope glycoproteins. A panel of recombinant envelope glycoproteins containing amino acids shared with either KB9 or KB9ct was tested for neutralization with plasma samples from the infected monkeys. Plasma samples from day 71 were used in this analysis, and CAT activity was normalized to the value observed in the presence of preimmune plasma for each virus; thus, a value of 1 designates no neutralization. The results of the neutralization assays are shown here for the following animals: KB9ct-infected animals 15865 (A), 11796 (B), 13939 (C), and 13898 (D) and KB9-infected animals 13930 (E), 13921 (F), and 13876 (G). The horizontal axes indicate the various recombinant envelope glycoproteins, and the vertical axes show the level of neutralization normalized to the value observed in the presence of preimmune plasma.

  • Fig. 5.
    • Open in new tab
    • Download powerpoint
    Fig. 5.

    Cross-neutralization of viruses with heterologous envelope glycoproteins by plasma from late time points after infection. Plasma samples from time points subsequent to day 71 were tested for neutralization of viruses with both KB9 (□) and KB9ct (⊕) envelopes. The horizontal axes indicate days postinfection. CAT activity was normalized to the value observed in the presence of preimmune plasma and is shown for the following infected animals: KB9ct-infected monkeys 15865 (A), 11796 (B), 13898 (C), and 13939 (D) and KB9-infected animals 13930 (E), 13921 (F), and 13876 (G).

  • Fig. 6.
    • Open in new tab
    • Download powerpoint
    Fig. 6.

    Neutralization of viruses with the divergent envelope glycoproteins. Entry of recombinant CAT virus with divergent envelope glycoproteins was tested in the presence of plasma from all infected monkeys at day 71, as well as the latest available time points. Results of neutralization assays using viruses with HXBc2 envelope glycoproteins (A and B), with ELI envelope glycoproteins (C and D), and with MN envelope glycoproteins (E and F) are shown. Horizontal axes designate days postinfection, and vertical axes show the level of neutralization normalized to the value observed in the presence of preimmune plasma. Symbols represent the monkeys designated, as shown.

Tables

  • Figures
  • Table 1.

    CD4+-lymphocyte counts and antibody response

    Envelope glycoproteinAnimal no.Seroconversiona (day postinfection)Lowest CD4 levelb(cells/μl)50% Plasma neutralizing activityc (day postinfection)
    KB9ct138981459028
    117961415529
    158651428625
    13939146643
    KB9138761710843
    139211412943
    13930145325
    13970NDd 21ND
    • ↵a Seroconversion was assessed by immunoprecipitation of 35S-labelled gp120 and gp160 envelope glycoproteins with plasma from different time points.

    • ↵b CD4+-lymphocyte levels were determined every 3 days after infection. The lowest CD4+-lymphocyte count observed in the first 4 weeks of infection is reported.

    • ↵c The ability of plasma (1:50 dilution) to neutralize the homologous virus was assessed and plotted for different time points after infection, and the time at which 50% of viruses were neutralized was approximated.

    • ↵d ND, not detected.

PreviousNext
Back to top
Download PDF
Citation Tools
Characterization of Simian-Human Immunodeficiency Virus Envelope Glycoprotein Epitopes Recognized by Neutralizing Antibodies from Infected Monkeys
Bijan Etemad-Moghadam, Gunilla B. Karlsson, Matilda Halloran, Ying Sun, Dominik Schenten, Mark Fernandes, Norman L. Letvin, Joseph Sodroski
Journal of Virology Oct 1998, 72 (10) 8437-8445; DOI: 10.1128/JVI.72.10.8437-8445.1998

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Journal of Virology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Characterization of Simian-Human Immunodeficiency Virus Envelope Glycoprotein Epitopes Recognized by Neutralizing Antibodies from Infected Monkeys
(Your Name) has forwarded a page to you from Journal of Virology
(Your Name) thought you would be interested in this article in Journal of Virology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Characterization of Simian-Human Immunodeficiency Virus Envelope Glycoprotein Epitopes Recognized by Neutralizing Antibodies from Infected Monkeys
Bijan Etemad-Moghadam, Gunilla B. Karlsson, Matilda Halloran, Ying Sun, Dominik Schenten, Mark Fernandes, Norman L. Letvin, Joseph Sodroski
Journal of Virology Oct 1998, 72 (10) 8437-8445; DOI: 10.1128/JVI.72.10.8437-8445.1998
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

epitopes
HIV Envelope Protein gp120
HIV-1
simian immunodeficiency virus

Related Articles

Cited By...

About

  • About JVI
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #Jvirology

@ASMicrobiology

       

 

JVI in collaboration with

American Society for Virology

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0022-538X; Online ISSN: 1098-5514